Current practices: immunosuppression induction, maintenance, and rejection regimens in contemporary post-heart...

Area of Science:

• Cardiology
• Immunology
• Transplantation Medicine

Background:

• Cardiac transplantation is a key treatment for end-stage cardiomyopathy.
• Survival rates have significantly improved over the past decade, largely due to cyclosporine-A.
• Cardiac allograft rejection is no longer the primary cause of early mortality post-transplant.

Purpose of the Study:

• To review current immunosuppression strategies in cardiac transplantation.
• To discuss the evolution of immunosuppression and emerging therapeutic agents.
• To highlight the ongoing challenge of balancing immunosuppression efficacy and toxicity.

Main Methods:

• Review of existing literature and clinical practices in cardiac transplantation immunosuppression.
• Discussion of multipronged immunosuppression approaches targeting various immune cascade sites.
• Examination of novel immunosuppressive agents and their mechanisms of action.

Main Results:

• Modern immunosuppression regimens have reduced the impact of cardiac allograft rejection on early survival.
• Newer agents like sirolimus, everolimus, and Daclizumab offer targeted immunosuppression.
• Practices in immunosuppression vary due to limited comparative trials.

Conclusions:

• Immunosuppression in cardiac transplantation requires a delicate balance to prevent rejection without causing excessive side effects.
• Ongoing research focuses on developing more specific and effective immunosuppressive agents.
• Further randomized trials are needed to guide optimal immunosuppression strategies.